Is complete really complete? Prognostic divergence of pathological complete response after FLOT versus CROSS in esophageal adenocarcinoma.
OBJECTIVE: To review whether pathological complete response (pCR) in esophageal adenocarcinoma (AC) may be regime-dependent and to outline its implications for surveillance, adjuvant therapy and trial design. Pathological complete response remains a favorable prognostic indicator relative to residual disease after neoadjuvant therapy, but postoperative ctDNA may further stratify recurrence risk within the pCR population.
OBJECTIVE: To review whether pathological complete response (pCR) in esophageal adenocarcinoma (AC) may be regime-dependent and to outline its implications for surveillance, adjuvant therapy and trial design. Pathological complete response remains a favorable prognostic indicator relative to residual disease after neoadjuvant therapy, but postoperative ctDNA may further stratify recurrence risk within the pCR population.
What the study was
- Study design
- Meta-analysis
- Sample size
- 465
- Category
- Early Detection
- Maturity
- Potentially Practice-Changing
- Journal
- European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Why it surfaced
High-priority Early cancer detection study: early cancer detection relevance warrants immediate pipeline escalation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.